Literature DB >> 28988916

Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.

Mette Julsgaard1, Jens Kjeldsen2, Bo M Bibby3, Birgitte Brock4, Daniel C Baumgart5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28988916     DOI: 10.1053/j.gastro.2017.08.067

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  5 in total

Review 1.  A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.

Authors:  Sherman Picardo; Cynthia H Seow
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

Review 2.  Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.

Authors:  Javier P Gisbert; María Chaparro
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

3.  Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review.

Authors:  Birgit Terjung; Renate Schmelz; Robert Ehehalt; Jochen Klaus; Jana Knop; Sabine Schwind; Thomas Wilke; Andreas Stallmach
Journal:  Therap Adv Gastroenterol       Date:  2020-10-16       Impact factor: 4.409

4.  Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease.

Authors:  Wan Sun; Blair Fennimore; Dawn B Beaulieu; Razvan Arsenescu; Adam C Stein; Jingjing Chen; Tiffany Lin; Sonya McKnight; Harisha Kadali; Maria Rosario; Richard A Lirio
Journal:  Clin Pharmacokinet       Date:  2021-02-05       Impact factor: 6.447

Review 5.  Insights into the treatment of inflammatory bowel disease in pregnancy.

Authors:  Sarah E Shannahan; Jonathan M Erlich; Mark A Peppercorn
Journal:  Therap Adv Gastroenterol       Date:  2019-05-27       Impact factor: 4.409

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.